Assessment of Brain Injury Marker (Carcinoembryonic Antigen) in Preeclamptic Pregnant Women in the Third Trimester of Pregnancy

Edebiri O.E; Akpe P. E.; Adewole A.S.; Mbanaso E.L.; Ikuenobe V. E.; Ohiwerei W.O.

doi:10.62951/ijhm.v2i1.364

Authors

Edebiri O.E Ambrose Alli University
Akpe P. E. University of Benin
Adewole A.S. University of Medical Science Teaching Hospital
Mbanaso E.L. Abia State University
Ikuenobe V. E. University of Benin
Ohiwerei W.O. Ohilux Global Research Institute

DOI:

https://doi.org/10.62951/ijhm.v2i1.364

Keywords:

Assessment, Carcinoembryonic Antigen (CEA), Glycoprotein, Preeclampsia, Pregnant Women

Abstract

Carcinoembryonic antigen (CEA) is a glycoprotein normally produced during fetal development, but presence of tissue damage and inflammation, its levels increase and this may be linked to Carcinoembryonic antigen in the pathophysiology of preeclampsia. This study aims to assess the level of Carcinoembryonic antigen (CEA) in preeclamptic pregnant women in the third trimester of pregnancy. Forty (40) consenting pregnant women were recruited from St. Philomina Catholic Hospital, Edo State, Nigeria. After the subjects were identified and recruited into the study, they were taken to the laboratory where their vital signs was taken and 10 milliliters (10 ml) of venous blood was drawn from consenting participants and placed in a lithium heparin sample bottles analyzed for Carcinoembryonic antigen (CEA) levels by fluorescence immunoassay. Data obtained from this study were analysed using Graph Pad Prism 9. Results generated were expressed as mean ± SEM and a P-value of ≤ 0.05 were considered statistically significant. The present study showed that there was statistically significant increase in the level of Brain injury marker (CEA) was observed in preeclamptic women compared to normotensive pregnant women, indicating various underlying pathophysiological processes such as Brain injury in preeclampsia.

Downloads

Download data is not yet available.

References

Álvarez-Chaver, P., Otero-Estévez, O., de la Cadena, M. P., Rodríguez-Berrocal, F. J., & Martínez-Zorzano, V. S. (2014). Proteomics for discovery of candidate colorectal cancer biomarkers. World Journal of Gastroenterology, 20(14), 3804. https://doi.org/xxxx

Armaly, Z., Jadaon, J. E., Jabbour, A., & Abassi, Z. A. (2018). Preeclampsia: Novel mechanisms and potential therapeutic approaches. Frontiers in Physiology, 9, 973. https://doi.org/xxxx

Asmanidar, A., & Emilda, E. (2024). Optimizing maternal healthcare: Holistic strategies for early detection and management of preeclampsia. Science Midwifery, 12(1), 158–167. https://doi.org/xxxx

Burd, E. M. (2010). Validation of laboratory-developed molecular assays for infectious diseases. Clinical Microbiology Reviews, 23(3), 550–576. https://doi.org/xxxx

Campos-da-Paz, M., Dórea, J. G., Galdino, A. S., Lacava, Z. G., & de Fatima Menezes Almeida Santos, M. (2018). Carcinoembryonic antigen (CEA) and hepatic metastasis in colorectal cancer: Update on biomarker for clinical and biotechnological approaches. Recent Patents on Biotechnology, 12(4), 269–279. https://doi.org/xxxx

Chappell, L. C., Seed, P. T., Briley, A., Kelly, F. J., Lee, P. A., & Shennan, A. H. (2013). Adverse perinatal outcomes associated with elevated C-reactive protein. Journal of Maternal-Fetal & Neonatal Medicine, 26(12), 1333–1338. https://doi.org/xxxx

Chevinsky, A. H. (1991, May). CEA in tumors of other than colorectal origin. In Seminars in Surgical Oncology, 7(3), 162–166. https://doi.org/xxxx

Duffy, M. J. (2001). Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful? Clinical Chemistry, 47(4), 624–630. https://doi.org/xxxx

Duley, L. (2009, June). The global impact of pre-eclampsia and eclampsia. In Seminars in Perinatology, 33(3), 130–137. https://doi.org/xxxx

Friis, T., Wikström, A. K., Acurio, J., León, J., Zetterberg, H., Blennow, K., … & Bergman, L. (2022). Cerebral biomarkers and blood-brain barrier integrity in preeclampsia. Cells, 11(5), 789. https://doi.org/xxxx

Galli, F., Aguilera, J. V., Palermo, B., Markovic, S. N., Nisticò, P., & Signore, A. (2020). Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. Journal of Experimental & Clinical Cancer Research, 39, 1–21. https://doi.org/xxxx

Gold, P., & Freedman, S. O. (1965). Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. The Journal of Experimental Medicine, 121(3), 439–462. https://doi.org/xxxx

Hao, C., Zhang, G., & Zhang, L. (2019). Serum CEA levels in 49 different types of cancer and noncancer diseases. Progress in Molecular Biology and Translational Science, 162, 213–227. https://doi.org/xxxx

Haram, K., Mortensen, J. H., & Mastrolia, S. A. (2018). HELLP syndrome: A review. Journal of Maternal-Fetal & Neonatal Medicine, 31(12), 1721–1728. https://doi.org/xxxx

Hayes, B., Murphy, C., Crawley, A., & O’Kennedy, R. (2018). Developments in point-of-care diagnostic technology for cancer detection. Diagnostics, 8(2), 39. https://doi.org/xxxx

Huppertz, B., Meiri, H., & Kaufmann, P. (2018). Placental oxidative stress and pre-eclampsia. Journal of Reproductive Immunology, 125, 108–114. https://doi.org/xxxx

Hussain, S., Mubeen, I., Ullah, N., Shah, S. S. U. D., Khan, B. A., Zahoor, M., … & Sultan, M. A. (2022). Modern diagnostic imaging technique applications and risk factors in the medical field: A review. BioMed Research International, 2022(1), 5164970. https://doi.org/xxxx

Jin, H. (2021). Perspectives of aptamers for medical applications. In Aptamers for Medical Applications: From Diagnosis to Therapeutics (pp. 405–462). https://doi.org/xxxx

Lee, J. W., & Colburn, W. A. (2001). Immunoassay techniques. In Handbook of Pharmaceutical Analysis (pp. 244–331). CRC Press. https://doi.org/xxxx

Lehtomäki, K. (2023). Quality of life and prognostic factors that aid treatment decision making in curatively treated colorectal cancer patients. https://doi.org/xxxx

Li, L., Yu, R., Cai, T., Chen, Z., Lan, M., Zou, T., … & Cai, Y. (2020). Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment. International Immunopharmacology, 88, 106939. https://doi.org/xxxx

Mach, P., Andrikos, D., Schmidt, B., Gellhaus, A., Rusch, P., Birdir, C., … & Köninger, A. (2021). Evaluation of carcinoembryonic antigen‐related cell adhesion molecule 1 blood serum levels in women at high risk for preeclampsia. American Journal of Reproductive Immunology, 85(5), e13375. https://doi.org/xxxx

Mach, P., Gellhaus, A., Prager, S., Moore, T., Wennemuth, G., Kimmig, R., … & Singer, B. B. (2017). Soluble CEACAM 1 and CEACAM 6 are differently expressed in blood serum of pregnant women during normal pregnancy. American Journal of Reproductive Immunology, 78(4), e12700. https://doi.org/xxxx

Ozdogan, H. K., Acar, E., Utkan, Z., Eraldemir, C., Kum, T., Kir, H., & Cekmen, M. B. (n.d.). Serum nitric oxide (NO), malondialdehyde (MDA), vascular endothelial growth factor (VEGF), endothelin (ET), interleukin-18, and interleukin-2 levels relationship between tumor size, grade, and lymph node metastasis in patients with breast cancer. [Nama jurnal jika tersedia]. https://doi.org/xxxx

Shao, Y., Sun, X., He, Y., Liu, C., & Liu, H. (2015). Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. PLOS ONE, 10(7), e0133830. https://doi.org/xxxx

Sibai, B. M., Ramin, S. M., & Friedman, S. A. (2017). Eclampsia: A guide for healthcare professionals. American Journal of Obstetrics and Gynecology, 217(3), 278–285. https://doi.org/xxxx

Yasmin, R. (2022). Point-of-care diagnostic devices in cancer detection (Doctoral dissertation, Brac University). https://doi.org/xxxx